After years of work, the outcomes of the MULTI-ACT project will be presented at the Final Conference, “The MULTI-ACT model: the path forward for participatory governance in health research and innovation”, to be held virtually on 23 March 2021 at 14:00-17:00.

The EU-funded MULTI-ACT project aims to increase the impact of health research on people with brain diseases. It has worked to create and implement a new model allowing for the effective cooperation of all relevant stakeholders, which will be applicable in defining the scope of health research as well as new metrics for the evaluation of its results. The MULTI-ACT project has worked with patients and patient organizations, academics, private and public stakeholders to develop brand new tools to assess the value of research.

Among these tools, the consortium has produced a governance model, a roadmap for patient engagement and impact indicators along five dimensions to foster stakeholder engagement in health research and innovation, which will be presented during the conference. Furthermore, the MULTI-ACT online toolbox will be presented and available for organisations to conduct health research with a multi-stakeholder and co-accountable approach.

EBC has been involved in a number of work packages within the MULTI-ACT project and is pleased to be leading the organisation of the Final Conference. Stay tuned for more details: registration will open at the beginning of March. For programme details, please see the programme below or visit the dedicated Event Page.

Learn more about the MULTI-ACT project by visiting: https://www.multiact.eu/, where a number of project brochures, videos, factsheets and full deliverables are shared!

MULTI-ACT Final conference-Programme

Striking the right balance between timely access to medicines and maintaining the highest standards of patient safety.

Introduction to the event

The event, hosted by the Swedish Brain Foundation, the Norwegian MS Association and the European Brain Council was held virtually on 24 November 2020. It brought together over 80 representatives from Norway and Sweden, and a distinguished list of speakers, – including physicians, patient organizations, pharmaceutical industry representatives and the authorities – to discuss the safety of medicines used off-label as well as the framework regulating their use. The workshop was sponsored by the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), Europe’s trade body for small to medium-sized innovative companies working in the field of pharmaceuticals and medical technologies.

A number of questions were considered, notably:

• In what situations is off-label use considered useful, and in what situations should it not occur?
• What are the drivers behind off-label use?
• What are the main consequences of off-label use? How does this affect patient care?

Below we have collected the main observations and areas of potential focus that emerged during the discussion. This could constitute a basis for interested stakeholders to discuss future initiatives and measures on off-label use.

Summary of the discussion

Background on off-label use

The use of off-label medicines plays an important role in modern healthcare systems, allowing patients to be treated in cases where an authorized drug is not available for a specific indication. This can be the case across a range of therapeutic areas, including rare diseases, pediatric cancers, palliative care and mental health.

However, off-label use can bring potentially increased risks for patients due to lack of clinical investigation or longer-term evaluation for a given indication or patient population, lack of informed consent, and difficulty in monitoring adverse events. Further complicating matters, there is a lack of an aligned strategy among agencies and decision makers regarding off-label use: different regions have different policy approaches and implementation. The use of off-label medicines when prescribed under the conditions laid out in the GOLUP Declaration, play an important role in medical practice and do not have a detrimental impact on pharmaceutical innovation. However, the use of off-label medicines for reasons other than a patient’s medical need has the potential to chill pharmaceutical innovation, as newly developed products and indications will not reach the patients they are intended to help.

Background on GOLUP Declaration

To maintain the highest levels of patient safety and minimize any adverse events, while not limiting the access to medications off-label when there is an unmet medical need, a number of organizations have established the Declaration on Good Off-Label Use Practice (so called GOLUP) as a series of baseline principles around good off-label use practice. Following a launch event in Brussels, workshops have been held in Rome and Madrid to present the GOLUP and discuss it with local stakeholders and decisionmakers.

The good practice criteria for off-label use included in the GOLUP Declaration include:

1. Presence of a medical therapeutic need based on a current examination of the patient by a suitably qualified health care professional;
2. Absence of authorized treatment and licensed alternatives tolerated by the patient or repeated treatment failure;
3. A documented review and critical appraisal of available scientific evidence favors off-label use to respond to the unmet medical need of the individual patient;
4. Patients (or their legal representative) must be given sufficient information about the medicines that are prescribed to allow them to make an informed decision;
5. Presence of established reporting routes for outcomes and adverse events linked to off-label use.

The drivers behind the off-label use of medicines in Sweden and Norway

In the daily reality of many doctors and patients in both countries, the prescription and use of medicines off-label is common practice. The point was made that the most common scenario for the use of an off-label medicine, and one generally well established in terms of regulation, should be where an authorized medicinal product is not available. It was highlighted that in Sweden, off-label use is particularly common in the pediatric space, where 49% of prescriptions are said to be off-label (79% for newborns).

When prescribing drugs to patients, doctors should look at a series of characteristics that are unique to every patient. Information on a therapy’s performance in a specific indication or dose, often lacking for off-label medicines, is pivotal to understand whether the treatment is adequate for the patient. For instance, multiple sclerosis is a heterogenous disease, which calls for personalized treatment. While some MS patients may benefit from off-label use, a one size approach does not work.

In Norway, physicians are currently incentivized to prescribe off-label for economic reasons, the practice of using off-label products as a means to save on healthcare costs, due to the recent cancellation of tenders for innovative MS products. This not only hinders professional autonomy to prescribe a different therapy if one is more medically appropriate, but also curtails patient choice in their treatment options.

The patients’ perspective

Patients have the right to be protected by a safe regulatory environment, to be fully informed and involved in treatment decisions, and to receive safe and effective treatments, which are backed by robust clinical trial data and regulatory approval. In Norway, healthcare professionals are supportive of the need for patients to play an active role in shared decision-making for their treatment. In Sweden, prescribers are required to discuss a full range of available on and off-label treatment options with the patient, and to choose one in agreement with the patient.  However, one participant observed that it is not easy to understand their physician’s recommendation or to provide informed input into this decision, as information on off-label therapies is not included in the pamphlets they are provided by their treatment center or hospital. There was agreement in the virtual room that patients must be adequately informed about potential side effects when being prescribed a medicine off-label, preferably in written form to allow for a discussion with their caregivers and families.

A suggested way forward

During the workshop, stakeholders agreed on the fact that off-label use is beneficial in many cases, but it can be detrimental to patient safety and access to innovative therapies. Above all else, the efficacy, safety and preservation of patient consent should be prioritized.

In conclusion the speakers highlighted areas of potential future focus:

• More information, that is user-friendly, should be provided to both patients and physicians. Patients need to be provided with concise, precise and trustworthy information, also in written form, in order for them to be fully informed and involved in treatment decisions;
• Data should be collected. Data should be collected and compiled for every treated patients and adverse events reported to the competent pharmacovigilance agency;

• Patient safety should be the top priority, and physicians should be given the latitude to prescribe the most appropriate treatments for their medical needs
• A stable regulatory framework should be maintained, with scientific assessments and patient need clearly separated from economic drivers.

You can download the report here.

Officially started on the 1^st of January 2021, the H2020 BRAINTEASER project kicked off its operational activities on 28 and 29 January, at the presence of its project officer Mr Tobias Wiesenthal, Head of Sector ‘Research and Innovation’ at DG CONNECT.H.3 – eHealth, Well-Being and Ageing.

All the 11 partners, a multidisciplinary gender-balanced consortium from academia, industry, clinical settings and the non-profit sector coming from six European countries, worked together during the two days’ meeting to streamline the project’s initial action plan, to confirm their roles and responsibilities and to commonly agree on the most effective strategies towards the project’s goals accomplishment.

The project consortium, led by the Universidad Politécnica de Madrid, will face the ambitious challenge of using Artificial Intelligence (AI) systems to process data gathered from patients affected by Multiple Sclerosis (MS) and Amyotrophic Lateral Sclerosis (ALS) to make patients’ management more efficient and effective and to develop models able to predict the diseases progression.

Amyotrophic Lateral Sclerosis and Multiple Sclerosis are two very complex degenerative neurological diseases but with very different clinical picture, evolution, prognosis and therapies. Common features are that both diseases affect the nervous system, they are chronic, progressive and modify significantly the quality of life of the patients and their families.

Patients have to manage alternated periods in hospital with care at home, experiencing a constant uncertainty regarding the timing of the disease acute phases and facing a considerable psychological and economic burden that also involves their family’s caregivers. Clinicians, on the other hand, need tools able to support them in all the phases of the patient’s treatment, suggest personalized therapeutic decisions and indicate urgently needed interventions.

During the four years of the project, the BRAINTEASER study will involve 300 patients enrolled in the four participating clinical centres located in Italy, Spain and Portugal. The patients will be constantly monitored using specific instruments such as sensors and smart apps, designing personalised services and fostering the patients’ empowerment and self-management.

The data collected, that will relate not only to clinical data but also to environmental, socio-economic data and lifestyle attitudes, will be integrated in comprehensive AI models to transform the current approach to health from reactive to predictive and to provide coaching tools, paving the path toward a healthier and more fulfilling life as long as possible.

The project’s multidisciplinary approach, guided by a strong accent on co-design methodologies that will involve the BRAINTEASER final users as part of its team in several phases, will bring great benefits to the patients, their family’s caregivers and for the clinicians, significantly enhancing the capacity of public health systems to predict, detect, alleviate and manage the negative impacts of those factors that contribute to the diseases causes, clinical progression and survival.

Ultimately, BRAINTEASER intends to become an open, significant success story of how, in the modern healthcare scenario, the integration of clinical knowledge, technical skills and patients’ contributions can drive towards innovative approaches to care and cure.

The project in a nutshell

• Project acronym: BRAINTEASER
• Full Title: BRinging Artificial INTelligencE home for a better cAre of amyotrophic lateral sclerosis and multiple SclERosis
• Start date: 1st January 2021
• Duration: 48 months
• Budget: €5.889.190
• Coordinator: Universidad Politécnica de Madrid

BRAINTEASER Consortium

• Universidad Politécnica de Madrid (Spain)
• Università degli Studi di Padova (Italy)
• FCIÊNCIAS.ID Associação para a Investigação e Desenvolvimento de Ciências (Portugal)
• Università degli Studi di Torino (Italy)
• Instituto De Medicina Molecular – João Lobo Antunes (Portugal)
• Servicio Madrileño de Salud (Spain)
• Fondazione Istituto Neurologico Nazionale Casimiro Mondino (Italy)
• Preduzeće za informacione tehnologije i elektronsko trgovanje Belit d.o.o. (Serbia)
• InSilicoTrials Technologies S.p.A (Italy)
• ECHAlliance Company Limited by Guarantee (Ireland)
• The European Brain Council (Belgium)

[1] van Es MA et al. The Lancet 2017 Nov 4;390(10107):2084-2098; Huisman M HB et al. Journal of Neurology, Neurosurgery & Psychiatry, 82(10), 1165- 1170; Hardiman O et al.J Neurol Neurosurg Psychiatry 88.7 (2017): 557-563

[1] Thompson AJ et al. Multiple sclerosis. Lancet 2018;391, 1622–1636.

DISCLAIMER

This project (BRAINTEASER) has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No GA101017598.
The content of this press release reflects only the authors’ views and the European Commission is not liable for any use that may be made of the information contained herein.